102 related articles for article (PubMed ID: 10849550)
21. Optimization of retroviral vector generation for clinical application.
Schilz AJ; Kühlcke K; Fauser AA; Eckert HG
J Gene Med; 2001; 3(5):427-36. PubMed ID: 11601756
[TBL] [Abstract][Full Text] [Related]
22. Reconstituting retroviral (ReCon) vectors facilitating delivery of cytotoxic genes in cancer gene therapy approaches.
Brandtner EM; Kodajova P; Hlavaty J; Jandl G; Tabotta W; Salmons B; Günzburg WH; Hohenadl C
J Gene Med; 2008 Feb; 10(2):113-22. PubMed ID: 18076132
[TBL] [Abstract][Full Text] [Related]
23. Transduction of human embryonic stem cells by ecotropic retroviral vectors.
Koch P; Siemen H; Biegler A; Itskovitz-Eldor J; Brüstle O
Nucleic Acids Res; 2006; 34(18):e120. PubMed ID: 16998181
[TBL] [Abstract][Full Text] [Related]
24. Effects of culture parameters on the production of retroviral vectors by a human packaging cell line.
McTaggart S; Al-Rubeai M
Biotechnol Prog; 2000; 16(5):859-65. PubMed ID: 11027182
[TBL] [Abstract][Full Text] [Related]
25. Superior transduction of mouse hematopoietic stem cells with 10A1 and VSV-G pseudotyped retrovirus vectors.
Barrette S; Douglas J; Orlic D; Anderson SM; Seidel NE; Miller AD; Bodine DM
Mol Ther; 2000 Apr; 1(4):330-8. PubMed ID: 10933951
[TBL] [Abstract][Full Text] [Related]
26. Construction of a retroviral vector production system with the minimum possibility of a homologous recombination.
Yu SS; Han E; Hong Y; Lee JT; Kim S; Kim S
Gene Ther; 2003 Apr; 10(8):706-11. PubMed ID: 12692599
[TBL] [Abstract][Full Text] [Related]
27. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
28. Characterization of an alternative packaging system derived from the cat RD114 retrovirus for gene delivery.
Ghani K; Cottin S; de Campos-Lima PO; Caron MC; Caruso M
J Gene Med; 2009 Aug; 11(8):664-9. PubMed ID: 19507185
[TBL] [Abstract][Full Text] [Related]
29. Streptavidin paramagnetic particles provide a choice of three affinity-based capture and magnetic concentration strategies for retroviral vectors.
Hughes C; Galea-Lauri J; Farzaneh F; Darling D
Mol Ther; 2001 Apr; 3(4):623-30. PubMed ID: 11319925
[TBL] [Abstract][Full Text] [Related]
30. Postoperative immuno-gene therapy of murine bladder tumor by in vivo administration of retroviruses expressing mouse interferon-gamma.
Shiau AL; Lin CY; Tzai TS; Wu CL
Cancer Gene Ther; 2001 Jan; 8(1):73-81. PubMed ID: 11219496
[TBL] [Abstract][Full Text] [Related]
31. A rapid procedure for screening fibroblast packaging cell lines for secretion of selectable retrovirus.
Elefanty AG; Cory S
Biotechniques; 1993 May; 14(5):770-4. PubMed ID: 8512701
[TBL] [Abstract][Full Text] [Related]
32. Transgene amplification and persistence after delivery of retroviral vector and packaging functions with E1/E4-deleted adenoviruses.
Torrent C; Jullien C; Klatzmann D; Perricaudet M; Yeh P
Cancer Gene Ther; 2000 Aug; 7(8):1135-44. PubMed ID: 10975674
[TBL] [Abstract][Full Text] [Related]
33. [Sorting of packaging cells for retroviral vector carrying green fluorescent gene and viral titer determination].
Zhang YG; Guo X; Zhou JJ; Yu B; Liu B
Di Yi Jun Yi Da Xue Xue Bao; 2005 Jan; 25(1):30-2, 36. PubMed ID: 15683992
[TBL] [Abstract][Full Text] [Related]
34. Growth factor displayed on the surface of retroviral particles without manipulation of envelope proteins is biologically active and can enhance transduction.
Chandrashekran A; Gordon MY; Darling D; Farzaneh F; Casimir C
J Gene Med; 2004 Nov; 6(11):1189-96. PubMed ID: 15468194
[TBL] [Abstract][Full Text] [Related]
35. Improved retroviral packaging lines derived from spleen necrosis virus.
Martinez I; Dornburg R
Virology; 1995 Apr; 208(1):234-41. PubMed ID: 11831705
[TBL] [Abstract][Full Text] [Related]
36. Suspension packaging cell lines for the simplified generation of T-cell receptor encoding retrovirus vector particles.
Reuss S; Biese P; Cosset FL; Takeuchi Y; Uckert W
Gene Ther; 2007 Apr; 14(7):595-603. PubMed ID: 17235289
[TBL] [Abstract][Full Text] [Related]
37. Scaleable purification process for gene therapy retroviral vectors.
Rodrigues T; Carvalho A; Carmo M; Carrondo MJ; Alves PM; Cruz PE
J Gene Med; 2007 Apr; 9(4):233-43. PubMed ID: 17428003
[TBL] [Abstract][Full Text] [Related]
38. Concentration of viral vectors by co-precipitation with calcium phosphate.
Pham L; Ye H; Cosset FL; Russell SJ; Peng KW
J Gene Med; 2001; 3(2):188-94. PubMed ID: 11318118
[TBL] [Abstract][Full Text] [Related]
39. Complexation with chondroitin sulfate C and Polybrene rapidly purifies retrovirus from inhibitors of transduction and substantially enhances gene transfer.
Landázuri N; Le Doux JM
Biotechnol Bioeng; 2006 Jan; 93(1):146-58. PubMed ID: 16240439
[TBL] [Abstract][Full Text] [Related]
40. Retroviral vector backbone immunogenicity: identification of cytotoxic T-cell epitopes in retroviral vector-packaging sequences.
Kondo E; Akatsuka Y; Nawa A; Kuzushima K; Tsujimura K; Tanimoto M; Kodera Y; Morishima Y; Kuzuya K; Takahashi T
Gene Ther; 2005 Feb; 12(3):252-8. PubMed ID: 15496958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
